Scarica l'app Stockscreener
1.19
2.46%
-0.03
Dopo l'orario di chiusura:
1.20
0.01
+0.84%
Precedente Chiudi:
$1.22
Aprire:
$1.21
Volume 24 ore:
1.33M
Relative Volume:
1.50
Capitalizzazione di mercato:
$50.70M
Reddito:
-
Utile/perdita netta:
$-40.92M
Rapporto P/E:
-0.6932
EPS:
-1.7167
Flusso di cassa netto:
$-26.53M
1 W Prestazione:
-13.77%
1M Prestazione:
-37.04%
6M Prestazione:
-53.88%
1 anno Prestazione:
-48.48%
Intervallo 1D:
$1.17
$1.26
Intervallo di 1 settimana:
$1.17
$1.44
Portata 52W:
$1.17
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.19 | 51.98M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - ad-hoc-news.de
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - Yahoo Finance
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - The Globe and Mail
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio, Inc. (ANVS) options chain - Yahoo Finance Singapore
Annovis Bio (ANVS) Edges Lower But Holds Above Key Support at $1.78Overvalued Signals - vinanet.vn
Annovis Bio Inc (ANVS) Stock News Today - TradingKey
Annovis Bio Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Annovis Bio (ANVS) Rallies 5% as Stock Approaches Key ResistanceDeath Cross - vinanet.vn
Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake - Stock Titan
ANVS|Annovis Bio Inc|Price:1.665|Chg%:+0.005 - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (ANVS) Gains 1.8% as Shares Hold Above Key Support at $1.61Short Term Trading Ideas - dars.gov.et
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):